285 related articles for article (PubMed ID: 12629413)
21. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells.
Geier R; Adler S; Rashid G; Klein A
Prostate; 2010 Sep; 70(12):1307-12. PubMed ID: 20623632
[TBL] [Abstract][Full Text] [Related]
22. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells.
Huang H; Zegarra-Moro OL; Benson D; Tindall DJ
Oncogene; 2004 Mar; 23(12):2161-76. PubMed ID: 14676836
[TBL] [Abstract][Full Text] [Related]
23. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
[TBL] [Abstract][Full Text] [Related]
25. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells.
Thelen P; Jarry H; Ringert RH; Wuttke W
Planta Med; 2004 May; 70(5):397-400. PubMed ID: 15124082
[TBL] [Abstract][Full Text] [Related]
26. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells.
Berchem GJ; Bosseler M; Sugars LY; Voeller HJ; Zeitlin S; Gelmann EP
Cancer Res; 1995 Feb; 55(4):735-8. PubMed ID: 7850782
[TBL] [Abstract][Full Text] [Related]
27. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
28. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.
Oosterhoff JK; Grootegoed JA; Blok LJ
Endocr Relat Cancer; 2005 Mar; 12(1):135-48. PubMed ID: 15788645
[TBL] [Abstract][Full Text] [Related]
29. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
[TBL] [Abstract][Full Text] [Related]
30. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
Rothermund CA; Kondrikov D; Lin MF; Vishwanatha JK
Prostate Cancer Prostatic Dis; 2002; 5(3):236-45. PubMed ID: 12496988
[TBL] [Abstract][Full Text] [Related]
31. Alteration of gene expression in response to bone morphogenetic protein-2 in androgen-dependent human prostate cancer LNCaP cells.
Kumagai T; Tomari K; Shimizu T; Takeda K
Int J Mol Med; 2006 Feb; 17(2):285-91. PubMed ID: 16391828
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
33. [Effect of dihydrotestosterone on the transcriptions and expressions of Smad3 and Smad4 in LNCaP cell line].
Gu RG; Zhou CW; Ma QZ
Zhonghua Nan Ke Xue; 2006 Mar; 12(3):211-4. PubMed ID: 16597033
[TBL] [Abstract][Full Text] [Related]
34. T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin.
Wolfgang CD; Essand M; Lee B; Pastan I
Cancer Res; 2001 Nov; 61(22):8122-6. PubMed ID: 11719440
[TBL] [Abstract][Full Text] [Related]
35. Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells.
Andrews P; Krygier S; Djakiew D
Cancer Chemother Pharmacol; 2002 Mar; 49(3):179-86. PubMed ID: 11935209
[TBL] [Abstract][Full Text] [Related]
36. Androgen signaling and post-transcriptional downregulation of Bcl-2 in androgen-unresponsive prostate cancer.
Rothermund CA; Gopalakrishnan VK; Vishwanatha JK
Prostate Cancer Prostatic Dis; 2004; 7(2):158-64. PubMed ID: 15124003
[TBL] [Abstract][Full Text] [Related]
37. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
Tsui KH; Feng TH; Chung LC; Chao CH; Chang PL; Juang HH
Anticancer Res; 2008; 28(4A):1969-76. PubMed ID: 18649734
[TBL] [Abstract][Full Text] [Related]
38. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
39. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
